AYTU Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
16.1M
+29.8%
12.4M
-18.2%
15.2M
+9.2%
13.9M
-8.2%
15.1M
Cost of Revenue
5.7M
+18.4%
4.8M
-13.2%
5.5M
+17.8%
4.7M
-3.7%
4.9M
Gross Profit
10.4M
+37.0%
7.6M
-21.0%
9.6M
+4.8%
9.2M
-10.4%
10.3M
Operating Expenses
11.2M
-4.1%
11.7M
+0.6%
11.6M
+8.5%
10.7M
-40.2%
17.9M
R&D
0
0
0
0
-100.0%
216.0K
SG&A
10.4M
-4.4%
10.9M
-1.5%
11.1M
+8.0%
10.2M
+20.9%
8.5M
Operating Income
-777000
+80.9%
-4064000
-106.3%
-1970000
-31.0%
-1504000
+80.3%
-7623000
EBITDA
344.0K
+111.7%
-2943000
-171.2%
-1085000
-54.8%
-701000
-133.3%
2.1M
Net Income
-15000
+99.7%
-5618000
+46.9%
-10584000
-638.6%
2.0M
+109.9%
-19818000
EPS (Basic)
$0.00
+100.0%
$-0.53
+49.5%
$-1.05
-600.0%
$0.21
+107.2%
$-2.92
EPS (Diluted)
$0.00
+100.0%
$-0.53
+49.5%
$-1.05
-1212.5%
$-0.08
—
Shares (Diluted)
9.3M
-12.0%
10.5M
+4.7%
10.0M
-48.5%
19.5M
—
AYTU BioPharma (AYTU) — Financials